INTRODUCTION
Overall survival in multiple myeloma (MM) has improved significantly over the last 30 years, 1 because of autologous hematopoietic progenitor cell (HPC) transplant (aHCT)-supported high-dose therapy 2 and the availability of novel agents, especially when incorporated into primary aHCT protocols. 2, 3 In the setting of relapsed MM, further aHCT salvage is superior to conventional chemotherapy. 4 Unfortunately, the current practice of collecting only sufficient HPC to support the planned initial aHCT leaves many relapsing patients without cryopreserved HPC. The variables determining the feasibility of HPC collection after prior aHCT were therefore investigated along with engraftment potential of such HPC following a salvage aHCT. The increasing concern about the risk of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) after MM therapy [5] [6] [7] prompted an investigation of variables linked to MDS-related cytogenetic abnormalities (MDS-CA) and clinical MDS/AML after the use of HPC collected following previous transplantation.
PATIENTS AND METHODS Patients
Records of patients who had received prior aHCT for symptomatic MM between January 2000 and January 2012 were reviewed to identify those in whom a post-aHCT HPC collection was attempted. Patient characteristics and mobilization regimens are shown in Table 1 . Mobilization regimens called for the subcutaneous administration of filgrastim (granulocyte colony-stimulating growth factor, 5 mg/kg) twice a day. Plerixafor, added for 56 patients in a total of 76 collections, was dosed subcutaneously at 240 mg/kg when the estimated glomerular filtration rate exceeded 50 mg/min per 1.73 m 2 (cap, 40 000 mg) and 160 mg/kg (cap, 27 000 mg) in case of lower glomerular filtration rate.
Methods
Laboratory data. We defined premobilization blood cell counts as the complete blood count obtained closest to the start of the mobilization regimen and no more than 30 days before the start of HPC collection. The same rule applied to bone marrow-derived data and to all other laboratory measurements. Metaphase karyotyping for detecting CA, typical of MM (MM-CA) or MDS (MDS-CA), 6, 8, 9 was part of each bone marrow examination. All MM-CA or MDS-CA determinations were made by one of the authors (JS, BB and XP). As bone marrow morphology can be altered by MM therapy 10 and MDS-CA can be transient or even not associated with clinically evident MDS, 6 we defined clinical MDS/AML as the condition for which specific MDS/AML therapy was required and administered. 10 Apheresis. HPC collection was performed using a COBE Spectra apheresis machine (TerumoBCT, Lakewood, CO, USA) to perform large volume leukapheresis (30 l processed) through a central venous catheter using 1000 ml anticoagulant citrate dextrose and 5000 units heparin for anticoagulation at an inlet: anti-coagulant ratio of 31:1 and an inlet flow rate of 150 ml/min with anticoagulant infused at 5 ml/min. Collection flow rate was set at 1.5 ml/min and 10 ml of anticoagulant citrate dextrose was added to the component at processed volumes of 10, 20 and 30 l.
An infusion of 2 g calcium chloride in 250 ml normal saline (0.9% sodium chloride) ran at 85 ml/h. Collection was guided by our predictive formula.
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Collection was started when the predicted collection was at least 0.5 Â 10 6 CD34 þ cells/kg and continued until the goal was met or the daily collection contained o0.5 Â 10 6 CD34 þ cells/kg.
Flow cytometry. Specimens drawn 1 h before apheresis were used to quantify CD34 þ cells/ml peripheral blood using the BD Procount kit (BD Biosciences, San Jose, CA, USA) on a FACSCalibur (BD Biosciences). These CD34 þ values were used in our predictive formula. 9 CD34 þ cells collected by apheresis were quantified by flow cytometry using the International Society for Hematotherapy and Graft Engineering protocol. 12 Time to engraftment. The day of HPC infusion was designated day 0. Neutrophil engraftment was defined as the second consecutive day of absolute neutrophil count X0.5 Â 10 9 /l. Platelet engraftment to X20 Â 10 9 /l and to X50 Â 10 9 /l was defined as the second consecutive day that an untransfused platelet count at or above these levels was documented.
Statistical methods. Differences between clinical and laboratory variables among selected patient populations were compared using two-tailed Student's t-tests, Mann-Whitney U-tests and univariate or multivariate analyses of binomial logistic regression where appropriate. For all analyses, Pp0.05 was considered statistically significant, while values 40.05 and p0.1 were considered as tending to statistical significance.
RESULTS

Patient characteristics
We identified 221 MM patients mobilized after at least one prior aHCT, for a total of 333 collections. The median age was 56 years (range 29-82) and 65% were males; 112 had one prior aHCT, 88 had two, and 21 had three or more such interventions (Table 1) . Prior relapses ranged from 1 to 13 (median, 2), and the median time from last aHCT was 4.2 years (range 0.1-12.4). Metaphase cytogenetics data were available for 209 of 333 collections (64%). Of these, 133 (64%) were normal, 72 (34%) were deemed MM-CA and 4 (2%) MDS-CA. MDS-CA at any time before a collection was documented in 22 of 333 collections (7%; Table 1 ). Data on bone marrow cellularity, morphology and degree of plasma cell infiltration were available within 1-month before mobilization for 217 of 333 collections (65%). MDS morphology was evident in 36 of 217 (16%) cases.
The median number of HPC collected before the first aHCT was 12.5 Â 10 6 CD34 þ /kg (range 0.7-87.6), which was accomplished in a median of 3 days (range [1] [2] [3] [4] [5] [6] [7] [8] Factors related to HPC yield and engraftment times after subsequent aHCT Other authors have suggested a minimum of 2.5 Â 10 6 CD34 þ cells/kg are required for successful engraftment. 13, 14 We therefore used this number as a collection threshold in determining mobilization variables. In univariate analysis, poor collection was linked to sole use of growth factors without chemotherapy (Po0.001, odds ratio (OR) 2.77), pre-collection hemoglobin o11 g/dl (P ¼ 0.032, OR 1.75) and platelet count o100 Â 10 9 /l (Po0.001, OR 2.43); participation in Total Therapy protocols (P ¼ 0.022, OR 2.14), female sex (P ¼ 0.047, OR 1.66) and low albumin o3.5 g/dl (P ¼ 0.003, OR 2.08) were additional adverse features (Table 2a) . Conversely, higher HPC yields were linked to the use of chemotherapy in the mobilization regimen (Po0.001, OR 0.38), the presence of MM-CA before mobilization (Po0.001, OR 0.06) 
Mobilization regimens
Abbreviations: ACE, adriamycin, cyclophosphamide, etoposide; aHCT, autologous hematopoietic progenitor cell transplant; BEAM, carmustine, etoposide, cytarabine, melphalan; C, cyclophosphamide; CA, cytogenetic abnormalities; CE, cyclophosphamide, etoposide; CRP, C-reactive protein; DCEP, dexamethasone, cyclophosphamide, etoposide, cisplatin; DT, dexamethasone, thalidomide; E, etoposide; Epo, erythropoietin; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; HPC, hematopoietic progenitor cell; MEL100, 100 mg/m 2 melphalan; MDS, myelodysplastic syndrome; MM, multiple myeloma; PACE, cisplatin, adriamycin, cyclophosphamide, etoposide; PACMED, cisplatin, cytarabine, cyclophosphamide, mesna, etoposide, dexamethasone; PEG-G-CSF, pegylated granulocyte colony-stimulating factor; VDT, bortezomib, dexamethasone, thalidomide.
and bone marrow cellularity480% (P ¼ 0.029, OR 0.10). In multivariate analysis, the only surviving adverse variables were platelet count o100 Â 10 9 /l (P ¼ 0.007, OR 2.56) and mobilization solely with growth factors (P ¼ 0.030, OR 2.34); the favorable effect of the presence of MM-CA is not understood (P ¼ 0.042, OR 0.06).
Of the 221 patients with HPC collections, 154 underwent a subsequent aHCT; the aHCT regimens are depicted in Supplementary Table 2 . The source of HPC in the graft was grouped as follows for analysis: 44 patients were grafted with HPC solely procured before the initial aHCT, 86 patients were grafted solely with cells procured after aHCT and 24 received a combination of both ('before', 'after' and 'both' groups, respectively; Table 3 ). The median numbers of infused HPC were 4.95, 4.49 and 4.36 Â 10 6 CD34 þ cells/kg in the three groups, respectively. Although neutrophil recovery to X0.5 Â 10 9 /l and platelet recovery X20 Â 10 9 /l was similar among the three groups, platelet engraftment X50 Â 10 9 /l occurred at medians of 15, 20 and 15 days, respectively, with the longest time seen in the 'after' group (Po0.001; Table 3 ). Neither bone marrow morphology, CA before aHCT, nor time elapsed from the most recent collection showed a statistical correlation with neutrophil or platelet engraftment times (data not shown). No statistically significant differences were noted in treatment-related mortality for the three groups (5%, 3.5% and 0% for 'before', 'after' and 'both' groups, respectively; P ¼ 0.766). Median overall survival and progression-free survival after aHCT was 14.7 and 5.8 months, with no statistical difference between the three graft groups (P ¼ 0.167 and P ¼ 0.238 for overall survival and progression-free survival, respectively).
MDS-CA and clinical MDS/AML after HPC collection Of the 221 patients in this study, MDS-CA developed in 11% (25/221), while clinical MDS/AML developed in 5% (12/221) after HPC collection. MDS-CA encounters are summarized in Supplementary Table 3 .
All factors evaluated for prediction of the collection yield as well as the number of CD34 þ cells collected were analyzed for their correlation with development of MDS-CA and clinical MDS/ AML after HPC collection. MDS-CA development after HPC collection was linked in univariate analysis to the presence of MDS-CA within 1-month before mobilization (P ¼ 0.009, OR 20.6), presence of MDS-CA at any time before mobilization (Po0.001, OR 9.70), hemoglobin o11 g/dl (P ¼ 0.016, OR 2.74), albumin o3.5 g/dl (P ¼ 0.030, OR 2.27) and poor collection (o2.5 Â 10 6 CD34 þ cells/kg; P ¼ 0.035, OR 2.59). In multivariate analysis, only the presence of MDS-CA at any time before mobilization and albumin concentration o3.5 g/dl were statistically significant (Po0.001, OR 11.6 and P ¼ 0.025, OR 3.13; Table 4 ).
As to clinical MDS/AML, presence of MDS-CA at any time before mobilization (P ¼ 0.001, OR 5.88) and albumin o3.5 g/dl (P ¼ 0.013, OR 3.56) were significant in univariate analysis. In multivariate analysis, albumin o3.5 g/dl and MDS-CA present at any time before mobilization showed a statistical tendency towards significance (P ¼ 0.058, OR 5.18 and P ¼ 0.076, OR 3.30; Table 4 ).
MDS-CA and clinical MDS/AML after aHCT
Development of MDS-CA and clinical MDS/AML after aHCT was seen in 8% (13/154) and 6% (10/154), respectively. All factors examined for engraftment times were used for statistical analysis. The use of a graft consisting solely of CD34 þ cells procured after HCT was the only factor significantly related to the subsequent development of MDS-CA (P ¼ 0.027, OR 10.34) and a tendency towards the development of clinical MDS/AML was also seen (P ¼ 0.091, OR 3.57).
DISCUSSION
Mobilization and collection following a previous aHCT is clearly feasible, as the majority of patients (74%) here collected a sufficient number of CD34 þ cells (X2.5 Â 10 6 /kg) for at least one aHCT. The pre-mobilization platelet count proved to be the most important factor in predicting a poor collection. This finding is in accord with earlier work from our institution in a similar population of previously transplanted patients. 15 Platelet count before mobilization has also been found to be predictive of successful HPC collection in a study at our institution of elderly The OR of a dichotomous variable for a given event represents the ratio of odds of a certain event happening when comparing the two possible outcomes. For continuous variables, the OR represents the same value for an increase of one unit of that variable. An OR 41 represents a positive correlation of the variable with the effect of interest (higher odds for the event of interest) while an ORo1 represents an adverse one (lower odds for the event of interest). HPC collection after autologous transplant for MM X Papanikolaou et al patients (470 years) without a history of aHCT. 16 An explanation for this finding may be the close relationship of megakaryopoietic commitment to the totipotent stem cell described in a novel model of sequential hematopoietic lineage commitment. 17 Also the association between the platelet count and the number of CD34 þ cells collected in this study could reflect a change in the 'cytokine microenvironment' of the bone marrow through chemotherapy 18, 19 and the plasma cell niche, of which the megakaryocytes are a functional part. 20 Another possible explanation is the potential co-existence of treatment-related MDS. Although a poor collection was linked to subsequent development of MDS-CA in our series of patients (P ¼ 0.035, OR 2.59), a low platelet count did not predict development of MDS (data not shown).
Prior Total Therapy protocol participation correlated with poor collection (P ¼ 0.022, OR 2.14), due in part to the preferential use of growth factors alone for mobilization in this patient subset (18/48 v 53/260 for the remainder, P ¼ 0.01). We found the use of growth factors alone for HPC mobilization predicted a 'poor' collection (P ¼ 0.001, OR 2.77). Although we have no explanation for the improved HPC collection seen here in the presence of MM-CA (Po0.001, OR 16.67), one may speculate that the higher proliferative capacity of MM with MM-CA (via thrombopoiesispromoting IL6) 21 and its greater stromal cell independence 22, 23 may both facilitate normal hematopoietic niche egress. 24, 25 Patients with either anemia (Hb o11 g/dl) or hypoalbulinemia (o3.5 g/dl) tended to be poor collectors (P ¼ 0.032, OR 1.75, P ¼ 0.003, OR 2.08, respectively). Given the effect of red blood cells on plasma volume and blood viscosity as well as the effect of hypoalbulinemia on blood viscosity 26 and poor collection, 16, 27 it could be that these two factors have an immediate effect on the 'physics' of the mononuclear cell layer formation during apheresis. Bone marrow cellularity was associated in two ways with the number of CD34 þ collected. Specifically, those with a cellularity o30% had a tendency towards poor collection (P ¼ 0.066, OR 1.86), whereas those with a cellularity 480% were associated with good collection (P ¼ 0.029, OR 0.10), perhaps reflecting the ability of stroma to support hematopoietic cells and therefore impact HPC mobilization.
The linkage of poor HPC collection after prior aHCT to female sex is in accord with large series of HPC collections in both healthy donors 28 and patients with hematological malignancies. 29 Chemotherapy-based mobilization proved to be most efficient in our cohort of patients, as has been shown in other settings. 13, 16 This implies that the basic clinical and biological facts that govern HPC mobilization 30 remain the same regardless of previous treatment history.
Mobilization regimens did not show a correlation with subsequent MDS-CA development or clinical MDS/AML, including plerixafor, which has recently been reported to predispose patients to clinical MDS/AML. 31 Plerixafor performed well in patients with a history of poor collection (o2.5 Â 10 6 CD34 þ cells/kg; 1.83 vs 3.43 Â 10 6 /kg, Po0.001), in agreement with experience in non-previously-transplanted patients. 32 Impaired renal function did not affect the ability of plerixafor to enhance collection.
In this series, as expected, the presence of MDS-CA within a month before mobilization (P ¼ 0.009, OR 20.6) and especially the presence of MDS-CA at any time before mobilization (Po0.001, OR 9.70) correlated with the subsequent development of MDS-CA and clinical MDS/AML in both univariate and multivariate analyses (Table 4) . We found poor collection (o2.5 Â 10 6 CD34 þ cells/kg; P ¼ 0.035, OR 2.59) was related to the development of subsequent MDS-CA (Table 4) , as previously reported. 6 The presence of anemia (hemoglobin o11 g/dl; P ¼ 0.016, OR 2.74) was also related to subsequent MDS-CA development, perhaps tied to the recent observation of erythropoietin gene promoter polymorphisms to the development of secondary MDS in MM patients. 33 Albumin concentration o3.5 g/dl was predictive not only of MDS-CA but also of clinical MDS/AML, and a trend was noted for elevated beta-2 microglobulin (Table 4 ). These two factors are markers of The OR of a dichotomous variable for a given event represents the ratio of odds of a certain event happening when comparing the two possible outcomes. For continuous variables, the OR represents the same value for an increase of one unit of that variable. An OR41 represents a positive correlation of the variable with the effect of interest (higher odds for the event of interest) while an ORo1 represents an adverse one (lower odds for the event of interest).
b Within 1-month before mobilization.
HPC collection after autologous transplant for MM X Papanikolaou et al more aggressive MM. Beta-2 microglobulin 45.5 g/dl has been shown to be related to the development of both MDS-CA and clinical MDS/AML in MM. 10 Use of an HPC graft consisting of cells procured after aHCT either alone or combined with cells collected before transplant did not affect treatment-related mortality of aHCT when compared with a graft consisting only of cells collected before the first aHCT. The delayed platelet engraftment seen in the 'after' vs 'before' (21 vs 15 days, Po0.001), and the 'after' vs 'both' groups (21 vs 15 days, P ¼ 0.003) is in agreement with previous findings. 15 HPC procured after an aHCT are functionally inferior to HPC collected early in the course of the disease before cumulative damage to the bone marrow from repeated or intense chemotherapy develops. The use of these cells alone as a graft, without the addition of cells collected earlier in the course of therapy, was the only factor in our data predisposing to MDS-CA development after aHCT (P ¼ 0.027, OR 10.34), and a statistical tendency for the development of clinical MDS/AML was also noted (P ¼ 0.091, OR 3.57). Since the effect of a salvage aHCT in MM is well established, 4, 34, 35 we suggest that adequate HPC for at least two aHCT be collected upfront in MM, especially if the findings of this study where the sole use of HPC procured after a previous aHCT effected MDS-CA and clinical MDS/AML development are confirmed by other studies.
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